Search

Displaying results 1241 - 1250 of 10000 in total
  1. Drug

    TrenibotulinumtoxinE

    go.drugbank.com/drugs/DB19082
    Approved

    [L64095] TrenibotulinumtoxinE is distinguished from the serotype A toxins that dominate this setting by its rapid onset and short duration: effects begin around 8 hours after injection, peak at day 7, … [L64095,L64118] It is given as an intramuscular injection into the corrugator and procerus muscles, is intended for occasional use, and its potency units are not interchangeable with those of other botulinum

  2. Drug

    Hexafluronium

    go.drugbank.com/drugs/DB00941
    Approved

    Hexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery.

  3. Drug

    Empagliflozin

    go.drugbank.com/drugs/DB09038
    ApprovedInvestigational

    [A203453] It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. … [A203501] Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g.

    Categories: P-glycoprotein substrates
  4. Drug

    Pemigatinib

    go.drugbank.com/drugs/DB15102
    ApprovedInvestigational

    growth factor receptor 2 (FGFR2) gene fusion or other rearrangements as detected by an FDA-approved test. … [A193719] FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  5. Drug

    Ibrutinib

    go.drugbank.com/drugs/DB09053
    ApprovedInvestigational

    It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. … Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    PF-03715455

    go.drugbank.com/drugs/DB12138
    Investigational

    PF-03715455 has been used in trials studying the treatment of Asthma, Pulmonary Disease, Chronic Obstructive, and Chronic Obstructive Pulmonary Disease (COPD).

  7. Drug

    PF-06459988

    go.drugbank.com/drugs/DB14768
    Investigational

    PF-06459988 is under investigation in clinical trial NCT02297425 (A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer).

  8. Drug

    Geraniol

    go.drugbank.com/drugs/DB14183
    Approved

    These pharmacologic effects are clinically important as geraniol is classified as generally-recognized-as-safe (GRAS) by the Flavor and Extract Manufacturers Association (FEMA) and the Food and Drug Administration … Sensitivity to geraniol may be identified with a clinical patch test.

  9. Drug

    Ditiocarb zinc

    go.drugbank.com/drugs/DB14193
    Approved

    Ditiocarb zinc, also known as Diethyldithiocarbamic acid zinc salt, is a known chelator for copper and zinc. It also a dermatological sensitizer and allergen. … Sensitivity to ditiocarb zinc may be identified with a clinical patch test.

    Categories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP2A6 Inhibitors
  10. Drug

    Iloprost

    go.drugbank.com/drugs/DB01088
    ApprovedInvestigational

    [A263326] Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47.[L50146] It is a potent vasodilator with reported anti-thrombotic properties. … Iloprost is an analog of prostacyclin (PGI2; epoprostenol), an endogenous prostanoid mainly produced in the vascular endothelium. It is more stable than prostacyclin, which is short-lived.

    Products: ILOMEDIN 0.5ML IV INJECTION, PULMOLİN 20 MCG/ML IV İNFÜZYONLUK ÇÖZELTİ, 1 ADET